Skip to Main Content

NEWS & RESOURCES

Bioscience

Positive Session for Bioscience Sector

The 2026 General Assembly session was one of the least contentious in recent memory for the biopharma sector. Bills calling for innovation-sapping price controls and unworkable programs…

Boehringer Partners on Connecticut Science Center STEM Lab

The Connecticut Science Center is home to exhibits, programs, and…

Costly Public Option Precursor Advances

The Connecticut General Assembly is exploring ways to address rising…

Content Type:

Bioscience

Connecticut Investing $100M in Cutting-Edge Industries

Connecticut is investing $100 million over the next five...

Bioscience

Successful Legislative Session for Biopharma

Scoring how well or poorly an industry group fared...

Bioscience

Commerce Committee Acts on Economic Development Measures

The legislature’s Commerce Committee acted March 21 on legislation...

Bioscience

Drug Pricing Bill Undermines Innovation

State lawmakers are considering a lengthy, complex bill with...

Bioscience

CBIA BizCast: Benefits of Whole Genome Sequencing

This episode of the CBIA BizCast is the first...

Bioscience

Rare Disease Day Focuses on ‘Diagnostic Odyssey’

Rare Disease Day is an opportunity to heighten awareness...

Bioscience

Bioscience Legislation Off to a Familiar Start

As the 2024 legislative session gains momentum, there are...

Bioscience

The Case Against Drug Price Negotiation

You may have heard that the federal government is...

Bioscience

Pfizer’s Hwang: ‘Connecticut Very Important to Us’

Pharmaceutical giant Pfizer has a long history of innovation,...

Stay Connected with CBIA News Digests

The latest news and information delivered directly to your inbox.